Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 6/20 | 0.51 |
| ▸ | SULT1A1 | P50225 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL10533655 | 0.90 | DYRK1A (0.57) | HTTGAAL3MBTL1CA12CA1 | |
| SCHEMBL27987130 | 0.84 | CA2 (0.53) | HTTGAAL3MBTL1CA2APP | |
| SCHEMBL334252 | 0.81 | NPC1 (0.61) | HTTGAAAPPKMT2ADYRK1A | |
| SCHEMBL10575044 | 0.80 | KMT2A (0.51) | HTTGAAL3MBTL1APPKMT2A | |
| SCHEMBL2217147 | 0.79 | HTT (0.66) | HTTGAAL3MBTL1CA12CA1 | |
| SCHEMBL1360479 | 0.78 | HTT (0.63) | HTTGAAL3MBTL1CA12CA1 | |
| SCHEMBL5756441 | 0.77 | MAPT (0.61) | HTTGAAL3MBTL1CA12CA1 | |
| SCHEMBL7643832 | 0.76 | HTT (0.61) | HTTGAAL3MBTL1CA12CA1 | |
| SCHEMBL141868 | 0.76 | RAB9A (0.51) | HTTGAAAPPKMT2ADYRK1A | |
| SCHEMBL21017367 | 0.76 | HTT (0.61) | HTTGAAL3MBTL1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0024525-B1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1982-06-30 | — | — | EP | claimed |
| EP-0024525-A1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1981-03-11 | — | — | EP | claimed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025064869-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-1996035681-A1 | BENZOTHIAZOLES AND BENZOXAZOLES, AS WELL AS DRUGS CONTAINING THEM, THEIR USE AND METHODS OF PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1996-11-14 | — | — | WO | disclosed |
| US-5424440-A | A non-fluorescent detector when hydrolyzing with selected enzyme become fluorescent; colorimetric analysis, spectrophotometry | JBL SCIENTIFIC, INC. (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0424465-A4 | PREPARATION AND USE OF FLUORESCENT BENZOTHIAZOLE DERIVATIVES | — | 1991-07-03 | — | — | EP | disclosed |
| EP-0424465-A1 | PREPARATION AND USE OF FLUORESCENT BENZOTHIAZOLE DERIVATIVES. | JBL SCIENT INC (US) | 1991-05-02 | — | — | EP | disclosed |
| WO-1990000618-A1 | PREPARATION AND USE OF FLUORESCENT BENZOTHIAZOLE DERIVATIVES | JBL SCIENTIFIC, INC. (US) | 1990-01-25 | — | — | WO | disclosed |
| US-4873346-A | BRONCHODILATORS, TREATMENT OF ASTHMA | THE UPJOHN COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| US-4826989-A | Process for the preparation of luciferin compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-02 | — | — | US | disclosed |
| EP-0024525-B1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1982-06-30 | — | — | EP | disclosed |
| EP-0024525-A1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | HTT 2559/4885GAA 4373/4885L3MBTL1 1998/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | HTT 2735/4885GAA 4054/4885L3MBTL1 2450/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | HTT 2539/4885GAA 3990/4885L3MBTL1 2221/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | HTT 3795/4885GAA 4746/4885L3MBTL1 3067/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | HTT 4720/4885GAA 2138/4885L3MBTL1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.